Original article here Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage by John Pinching | 7th May 2026 | News Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the company’s Callavid …

CLCC was delighted to have taken part in the Cleveland Clinic Global Women’s Health Forum, co-hosted by the Women’s Alzheimer’s Movement and Maria Shriver. It was an inspiring gathering of voices across medicine, research, advocacy, and innovation, with important conversations spanning heart and brain health, strength, mental wellbeing, financial health, and more. 💪 Our co-founder …

Original article here by Geri Stengel   Picture the pitch room. Dr. Lara Zibners has a question for the male-majority audience. “How many of you have put medication up your nose?” A few hands go up. Then: “…besides cocaine.” Laughter. Then the turn: if nasal drugs leaked the way vaginal drugs do, one of them …

We are delighted and honoured that Callavid® has been named in this National Institute for Health and Care Research (NIHR) news story highlighting the role NIHR is playing in improving outcomes for women through the UK Government’s revised Women’s Health Strategy. 🇬🇧 As NIHR notes: “NIHR is funding ‘Callavid’ which if approved would be the …

Our colleagues Andrew Lewis and Elham Shirani will be at the third Microbes in Women’s Health Congress in Valencia on 21-22 April. 🇪🇸 We’re excited to meet with existing and new partners for 2 days of talks, panels and networking.  Our user convenient Callavid® drug delivery platform will help provide effective colonisation and epithelial adherence …

original article here: https://drug-dev.com/expert-content/the-most-underutilized-route-in-drug-delivery-how-vaginal-therapeutics-are-finally-getting-the-platform-they-deserve/ The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve By: Lara Zibners, MD, MMEd, MBA Women are: 51% of the population The majority of prescription drug users (QuickStats, MMWR, 2023) Almost always the medical decision maker for the family (US Dept of Labor) And, …

Inspired by two packed days at the inaugural HERS summit in sunny San Diego ☀️ with such clear momentum across women’s health. But what was particularly energising and impressive was seeing several scientific breakthroughs and growing successes emerging across the space. None of which have been easy. They’ve all been very hard fought, against the …

Calla Lily Clinical Care will be in sunny Southern California!  ☀️ We’re delighted to be in Dana Point, CA during the LSI conference from March 16th-20th – one of medtech’s premier partnering events. We’ll also be in San Diego, CA for the Women’s Health Executive & Research Summit (HERS) conference from March 23-24th – an inaugural …

In the beautiful surroundings of Fishmongers Hall in the City of London, it was great to see our co-founder, Lara Zibners MD MMEd MBA, take part in the WHH Women’s Health Horizons event. Her panel, “From Innovation to Impact: Navigating the Complexities of Medical Device Development in Women’s Health,” was extremely well received, reflecting both …

I recently had the privilege of sharing my thoughts on representing Calla Lily Clinical Care in the Milken Institute Health Women’s Health Network while at the London event a few weeks ago. Yes, that is me grabbing a photo with the former first lady. One of the points that I made during my interview was …